Last 12 months
Inside the activity.
1 purchase rows · 32 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 8 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 14 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 28, 2018 Filed Dec 1, 2018 01:02 UTC |
Hessekiel JeffreyEVP and General Counsel
|
SaleCommon Stock | 11,759 | $19.12 | $224,832.08 |
DisclosureSEC source: 0000939767-18-000242 · wf-form4_154362610864788.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,879 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.11 to $19.13. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 45,624 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 27, 2018 Filed Jan 5, 2019 01:50 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GiftCommon Stock | 17,647 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000006 · wf-form4_154665301832587.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 193,998 F1 · kind: On November 27, 2018, the reporting person gifted 17,647 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended. F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. Read SEC document |
| November 27, 2018 Filed Jan 5, 2019 01:50 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GiftCommon Stock | 17,647 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000006 · wf-form4_154665301832587.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F1 · kind: On November 27, 2018, the reporting person gifted 17,647 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended. F2 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:26 UTC |
Senner Christopher J.EVP and CFO
|
Tax withholdingCommon Stock | 1,882 | $17.45 | $32,840.90 |
DisclosureSEC source: 0000939767-18-000238 · wf-form4_154241798611264.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,741 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:26 UTC |
Senner Christopher J.EVP and CFO
|
Tax withholdingCommon Stock | 5,882 | $17.45 | $102,640.90 |
DisclosureSEC source: 0000939767-18-000238 · wf-form4_154241798611264.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,623 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 56,875 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,008 shares of common stock acquired on April 30, 2018, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:24 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Tax withholdingCommon Stock | 2,479 | $17.45 | $43,258.55 |
DisclosureSEC source: 0000939767-18-000236 · wf-form4_154241785504509.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:24 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Tax withholdingCommon Stock | 9,296 | $17.45 | $162,215.20 |
DisclosureSEC source: 0000939767-18-000236 · wf-form4_154241785504509.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,992 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:22 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0000939767-18-000234 · wf-form4_154241771592566.xml · derivative · entry 7 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2019-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 25,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 26, 2013. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:22 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 25,000 | $17.22 | $430,500.00 |
DisclosureSEC source: 0000939767-18-000234 · wf-form4_154241771592566.xml · nonDerivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,647 F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.16 to $17.30. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:22 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 25,000 | $4.42 | $110,500.00 |
DisclosureSEC source: 0000939767-18-000234 · wf-form4_154241771592566.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:22 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Tax withholdingCommon Stock | 7,437 | $17.45 | $129,775.65 |
DisclosureSEC source: 0000939767-18-000234 · wf-form4_154241771592566.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,647 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 26, 2016. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:22 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Tax withholdingCommon Stock | 9,916 | $17.45 | $173,034.20 |
DisclosureSEC source: 0000939767-18-000234 · wf-form4_154241771592566.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,084 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:19 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Tax withholdingCommon Stock | 2,098 | $17.45 | $36,610.10 |
DisclosureSEC source: 0000939767-18-000232 · wf-form4_154241753222888.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,197 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:19 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Tax withholdingCommon Stock | 7,101 | $17.45 | $123,912.45 |
DisclosureSEC source: 0000939767-18-000232 · wf-form4_154241753222888.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,295 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 49,374 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:16 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Tax withholdingCommon Stock | 1,404 | $17.45 | $24,499.80 |
DisclosureSEC source: 0000939767-18-000230 · wf-form4_154241737191595.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,638 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:16 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Tax withholdingCommon Stock | 4,408 | $17.45 | $76,919.60 |
DisclosureSEC source: 0000939767-18-000230 · wf-form4_154241737191595.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,042 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 45,624 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:12 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
Tax withholdingCommon Stock | 2,909 | $17.45 | $50,762.05 |
DisclosureSEC source: 0000939767-18-000228 · wf-form4_154241715543311.xml · nonDerivative · entry 2 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,011 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:12 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
Tax withholdingCommon Stock | 6,197 | $17.45 | $108,137.65 |
DisclosureSEC source: 0000939767-18-000228 · wf-form4_154241715543311.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,920 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 49,234 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,200 shares of common stock acquired on October 31, 2018, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| November 07, 2018 Filed Nov 10, 2018 00:56 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 20,000 | $17.32 | $346,400.00 |
DisclosureSEC source: 0000939767-18-000226 · wf-form4_154181140006002.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,917 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.31 to $17.36. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 67,602 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 02, 2018 Filed Nov 3, 2018 00:02 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 37,499 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000939767-18-000222 · wf-form4_154120333141663.xml · derivative · entry 7 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,499 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 16, 2012. Read SEC document |
| November 02, 2018 Filed Nov 3, 2018 00:02 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 100 | $19.03 | $1,903.00 |
DisclosureSEC source: 0000939767-18-000222 · wf-form4_154120333141663.xml · nonDerivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2018. Read SEC document |
| November 02, 2018 Filed Nov 3, 2018 00:02 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 4,044 | $18.22 | $73,681.68 |
DisclosureSEC source: 0000939767-18-000222 · wf-form4_154120333141663.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,100 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2018. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.99 to $18.81. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| November 02, 2018 Filed Nov 3, 2018 00:02 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 33,355 | $17.49 | $583,378.95 |
DisclosureSEC source: 0000939767-18-000222 · wf-form4_154120333141663.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,144 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.98 to $17.97. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| November 02, 2018 Filed Nov 3, 2018 00:02 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 37,499 | $5.04 | $188,994.96 |
DisclosureSEC source: 0000939767-18-000222 · wf-form4_154120333141663.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 125,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:05 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionOption (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000939767-18-000224 · wf-form4_154120348927155.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,499 Underlying: Common Stock · 12,000 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 16, 2012. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:05 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
SaleCommon Stock | 12,000 | $14.16 | $169,920.00 |
DisclosureSEC source: 0000939767-18-000224 · wf-form4_154120348927155.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,288 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.89 to $14.39. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:05 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock | 12,000 | $5.04 | $60,480.00 |
DisclosureSEC source: 0000939767-18-000224 · wf-form4_154120348927155.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:03 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 10,000 | $14.14 | $141,400.00 |
DisclosureSEC source: 0000939767-18-000223 · wf-form4_154120341758722.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,511,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.92 to $14.22. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:03 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 15,000 | $15.00 | $225,000.00 |
DisclosureSEC source: 0000939767-18-000223 · wf-form4_154120341758722.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,521,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:12 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 25,000 | $17.86 | $446,500.00 |
DisclosureSEC source: 0000939767-18-000210 · wf-form4_153861195132768.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,536,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.67 to $17.93. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:11 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 12,501 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000939767-18-000209 · wf-form4_153861188167418.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,499 Underlying: Common Stock · 12,501 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 16, 2012. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:11 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 12,501 | $17.82 | $222,767.82 |
DisclosureSEC source: 0000939767-18-000209 · wf-form4_153861188167418.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.64 to $17.94. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:11 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 12,501 | $5.04 | $63,005.04 |
DisclosureSEC source: 0000939767-18-000209 · wf-form4_153861188167418.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 125,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:08 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionOption (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000939767-18-000208 · wf-form4_153861170606263.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,499 Underlying: Common Stock · 12,000 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 16, 2012. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:08 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
SaleCommon Stock | 12,000 | $17.77 | $213,240.00 |
DisclosureSEC source: 0000939767-18-000208 · wf-form4_153861170606263.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,288 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.65 to $17.93. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:08 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock | 12,000 | $5.04 | $60,480.00 |
DisclosureSEC source: 0000939767-18-000208 · wf-form4_153861170606263.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 23:40 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 25,000 | $16.85 | $421,250.00 |
DisclosureSEC source: 0000939767-18-000204 · wf-form4_153800521414604.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,561,981 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.71 to $16.94. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:17 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
GrantOption (right to buy) · Derivative | 124,341 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-18-000202 · wf-form4_153679780365221.xml · derivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,341 Underlying: Common Stock · 124,341 shares Expires 2025-09-09 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:14 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
GrantOption (right to buy) · Derivative | 129,314 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-18-000201 · wf-form4_153679763393195.xml · derivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,314 Underlying: Common Stock · 129,314 shares Expires 2025-09-09 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:11 UTC |
Hessekiel JeffreyEVP and General Counsel
|
GrantOption (right to buy) · Derivative | 129,314 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-18-000200 · wf-form4_153679746370589.xml · derivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,314 Underlying: Common Stock · 129,314 shares Expires 2025-09-09 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:07 UTC |
Senner Christopher J.EVP and CFO
|
GrantOption (right to buy) · Derivative | 129,314 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-18-000199 · wf-form4_153679725190426.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,314 Underlying: Common Stock · 129,314 shares Expires 2025-09-09 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:03 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GrantOption (right to buy) · Derivative | 308,365 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-18-000197 · wf-form4_153679701780301.xml · derivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,365 Underlying: Common Stock · 308,365 shares Expires 2025-09-09 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. However, the option will not be exercisable until the closing market price of Exelixis, Inc. common stock is equal to or greater than 125% of the exercise price of the option over a period of at least 30 consecutive calendar days. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:06 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
GrantOption (right to buy) · Derivative | 116,383 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-18-000198 · wf-form4_153679716206165.xml · derivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,383 Underlying: Common Stock · 116,383 shares Expires 2025-09-09 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| September 04, 2018 Filed Sep 7, 2018 00:00 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock · Derivative | 22,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000190 · wf-form4_153627839293160.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2018-09-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015. Read SEC document |
| September 04, 2018 Filed Sep 7, 2018 00:00 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
SaleCommon Stock | 22,500 | $18.53 | $416,925.00 |
DisclosureSEC source: 0000939767-18-000190 · wf-form4_153627839293160.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,288 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.37 to $18.70. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| September 04, 2018 Filed Sep 7, 2018 00:00 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock | 22,500 | $5.50 | $123,750.00 |
DisclosureSEC source: 0000939767-18-000190 · wf-form4_153627839293160.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 20, 2018 Filed Aug 23, 2018 00:10 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 90,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000188 · wf-form4_153498303768700.xml · derivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2018-09-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 450,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015. Read SEC document |
| August 20, 2018 Filed Aug 23, 2018 00:10 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 86,200 | $17.79 | $1,533,498.00 |
DisclosureSEC source: 0000939767-18-000188 · wf-form4_153498303768700.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2018. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.42 to $18.32. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| August 20, 2018 Filed Aug 23, 2018 00:10 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 3,800 | $18.61 | $70,718.00 |
DisclosureSEC source: 0000939767-18-000188 · wf-form4_153498303768700.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,200 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.42 to $18.70. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| August 20, 2018 Filed Aug 23, 2018 00:10 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 90,000 | $5.50 | $495,000.00 |
DisclosureSEC source: 0000939767-18-000188 · wf-form4_153498303768700.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 125,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.